AstraZeneca collaborates with MIOTIFY to test MIOTIFY’s ‘Compliant Component’ approach for deploying algorithms into digital patient solutions
“AZ undertake >100 clinical trials annually to support development of novel therapeutics and intends to use validated digital platforms both to accelerate the development of these novel products, and also to deliver digital therapeutic solutions to improve outcomes for our patients. Delivering these objectives requires AZ to develop and validate medical device grade software solutions and a component based approach enabled by MIOTIFY’s platform has the potential to standardise the approach to deploying algorithms ranging from standard algorithms used to transform data from devices/sensors for remote monitoring in clinical trials to supporting the deployment and ongoing monitoring of more complex algorithms to be used in digital therapeutics leading to enhanced outcomes for patients.”
Matt Bonam, Head, BioPharmaceuticals R&D Digital Patient Health, AstraZeneca (AZ)
“MIOTIFY is committed to working with both innovators and regulatory stakeholders to empower the advancement of healthcare by fostering responsible and high-quality digital health innovation with a platform for providing efficient and least burdensome oversight, while meeting the regulatory standards for safe and effective products”
Sheena Macpherson, Founder and CEO, MIOTIFY LTD.